These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12419377)

  • 1. Novel spirocyclic pyrrolidones as P2/P1 mimetics in potent inhibitors of HIV-1 protease.
    Kazmierski WM; Furfine E; Spaltenstein A; Wright LL
    Bioorg Med Chem Lett; 2002 Dec; 12(23):3431-3. PubMed ID: 12419377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent pyrrolidone-based HIV-1 protease inhibitors with enhanced drug-like properties.
    Kazmierski WM; Andrews W; Furfine E; Spaltenstein A; Wright L
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5689-92. PubMed ID: 15482949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of stereochemically defined novel spirocyclic P2-ligands for HIV-1 protease inhibitors.
    Ghosh AK; Chapsal BD; Baldridge A; Ide K; Koh Y; Mitsuya H
    Org Lett; 2008 Nov; 10(22):5135-8. PubMed ID: 18928291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.
    Ghosh AK; Leshchenko-Yashchuk S; Anderson DD; Baldridge A; Noetzel M; Miller HB; Tie Y; Wang YF; Koh Y; Weber IT; Mitsuya H
    J Med Chem; 2009 Jul; 52(13):3902-14. PubMed ID: 19473017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.
    Spaltenstein A; Almond MR; Bock WJ; Cleary DG; Furfine ES; Hazen RJ; Kazmierski WM; Salituro FG; Tung RD; Wright LL
    Bioorg Med Chem Lett; 2000 Jun; 10(11):1159-62. PubMed ID: 10866371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.
    Ghosh AK; Sean Fyvie W; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4925-4931. PubMed ID: 28958624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic sulfamide HIV-1 protease inhibitors, with sidechains spanning from P2/P2' to P1/P1'.
    Ax A; Schaal W; Vrang L; Samuelsson B; Hallberg A; Karlén A
    Bioorg Med Chem; 2005 Feb; 13(3):755-64. PubMed ID: 15653343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of pyrrolidinone based HIV protease inhibitors.
    Sherrill RG; Andrews CW; Bock WJ; Davis-Ward RG; Furfine ES; Hazen RJ; Rutkowske RD; Spaltenstein A; Wright LL
    Bioorg Med Chem Lett; 2005 Jan; 15(1):81-4. PubMed ID: 15582415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unsymmetrical cyclic ureas as HIV-1 protease inhibitors: novel biaryl indazoles as P2/P2' substituents.
    Patel M; Rodgers JD; McHugh RJ; Johnson BL; Cordova BC; Klabe RM; Bacheler LT; Erickson-Viitanen S; Ko SS
    Bioorg Med Chem Lett; 1999 Nov; 9(22):3217-20. PubMed ID: 10576691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of novel conformationally restricted HIV protease inhibitors.
    Salituro FG; Baker CT; Court JJ; Deininger DD; Kim EE; Li B; Novak PM; Rao BG; Pazhanisamy S; Porter MD; Schairer WC; Tung RD
    Bioorg Med Chem Lett; 1998 Dec; 8(24):3637-42. PubMed ID: 9934485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
    Smith AB; Charnley AK; Harada H; Beiger JJ; Cantin LD; Kenesky CS; Hirschmann R; Munshi S; Olsen DB; Stahlhut MW; Schleif WA; Kuo LC
    Bioorg Med Chem Lett; 2006 Feb; 16(4):859-63. PubMed ID: 16298527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.
    Lindberg J; Pyring D; Löwgren S; Rosenquist A; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Classon B; Hallberg A; Samuelsson B; Unge T
    Eur J Biochem; 2004 Nov; 271(22):4594-602. PubMed ID: 15560801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and conformational analysis of a novel series of HIV protease inhibitors.
    Baker CT; Salituro FG; Court JJ; Deininger DD; Kim EE; Li B; Novak PM; Rao BG; Pazhanisamy S; Schairer WC; Tung RD
    Bioorg Med Chem Lett; 1998 Dec; 8(24):3631-6. PubMed ID: 9934484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold.
    Kazmierski WM; Furfine E; Gray-Nunez Y; Spaltenstein A; Wright L
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5685-7. PubMed ID: 15482948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New, potent P1/P2-morpholinone-based HIV-protease inhibitors.
    Kazmierski WM; Furfine E; Spaltenstein A; Wright LL
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5226-30. PubMed ID: 16904316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities.
    Hultén J; Bonham NM; Nillroth U; Hansson T; Zuccarello G; Bouzide A; Aqvist J; Classon B; Danielson UH; Karlén A; Kvarnström I; Samuelsson B; Hallberg A
    J Med Chem; 1997 Mar; 40(6):885-97. PubMed ID: 9083477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mechanistic study of 3-aminoindazole cyclic urea HIV-1 protease inhibitors using comparative QSAR.
    Garg R; Bhhatarai B
    Bioorg Med Chem; 2004 Nov; 12(22):5819-31. PubMed ID: 15498658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.
    Ghosh AK; Schiltz G; Perali RS; Leshchenko S; Kay S; Walters DE; Koh Y; Maeda K; Mitsuya H
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1869-73. PubMed ID: 16480871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis.
    Nugiel DA; Jacobs K; Cornelius L; Chang CH; Jadhav PK; Holler ER; Klabe RM; Bacheler LT; Cordova B; Garber S; Reid C; Logue KA; Gorey-Feret LJ; Lam GN; Erickson-Viitanen S; Seitz SP
    J Med Chem; 1997 May; 40(10):1465-74. PubMed ID: 9154969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-Hydroxy-1,3-dioxin-4-ones as non-peptidic HIV protease inhibitors.
    Lee YS; Lee YS; Lee JY; Kim SN; Lee CK; Park H
    Bioorg Med Chem Lett; 2000 Dec; 10(23):2625-7. PubMed ID: 11128638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.